^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

A phase II biomarker-oriented study to evaluate paclitaxel, olaparib, and durvalumab combination in patients with advanced gastric cancer.

Published date:
01/17/2023
Excerpt:
Fifty pts were enrolled (6 screening fail or withdrawal of consent, 44 in SS, 38 in ES) HER2+ GC were 13.2%. Among 38 in ES, DCR and ORR were 84.1% (95% CI, 72.5-95.7) and 39.5% (95% CI, 24.0-55.0) (1 CR, 14 PR and 17 SD). PFS, DoR and OS were 6.7 (95% CI, 4.5-10.3), 6.5 (95% CI, 5.1-10.7) and 11.4 (95% CI, 9.2-13.2) months...Paclitaxel/olaparib/durvalumab is a promising combination in 2L GC...
Secondary therapy:
paclitaxel
DOI:
10.1200/JCO.2023.41.3_suppl.404
Trial ID: